Analyysi
Back to business
The capital raise announced on Friday reduces the financing risks and secures the company’s financing until early 2025. We expect the raise to succeed. With short-term funding in check, SciBase can focus again on executing its growth strategy in US, where clear signs of success could be emerging starting in 2025. We highlight the special situation of the stock due to the upcoming ex-unit right date and the very large number of warrants.
Sisäänkirjautuminen vaadittu
Tämä sisältö on näkyvissä vain sisäänkirjautuneille käyttäjille
Scibase Holding is a global medical technology group specialized in diagnostics and prevention in dermatology. The company develops, produces and commercializes Nevisense, a patient-centered platform that combines AI (artificial intelligence) with EIS technology to enable early detection and intervention of skin cancer and other skin diseases. Nevisense is based on over 20 years of research at Karolinska Institutet, the headquarters are in Stockholm.
Lue lisää yhtiösivullaFoorumin keskustelut
